generation run 2026-05-11
58 min completedmodel pipeline-v5plan not recordedrun/217f1079…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- sparse_evidence
- structural_inference
Reproduce
- inputs
- 27 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
17 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubMed | isopropylphenidate pharmacology | 5 | 4 | All directly relevant to IPH pharmacology and toxicology |
| 2 | ClinicalTrials.gov · absence | isopropylphenidate | 0 | 0 | No trials exist; gap to note in output |
| 3 | PubMed | isopropylphenidate IPH stimulant | 2 | 2 | Already captured; no new results |
| 4 | PubChem | isopropylphenidate | 1 | 1 | Primary chemical identity data for isopropylphenidate |
| 5 | PubMed | methylphenidate carboxylesterase hydrolysis ethanol transesterification | 2 | 1 | Relevant to IPH's reduced CES1 interaction advantage |
| 6 | OpenAlex | methylphenidate phenidate new psychoactive substances forensic detection | 10 | 4 | Phenidate class forensic characterization, safety context, and comparative pharmacology |
| 7 | OpenAlex | isopropylphenidate pharmacology dopamine | 10 | 4 | Provide NPS class context and adverse effect profiles for phenidates |
| 8 | PubMed/Crossref DOI verification | DOI 10.1089/cap.2013.0074 | 1 | 1 | Verification of primary pharmacology paper |
| 9 | WebSearch | isopropylphenidate Canada Schedule III controlled drugs substances | 10 | 1 | Canada scheduling confirmed |
| 10 | WebSearch (via Grokipedia) | isopropylphenidate pharmacological data | 1 | 3 | Specific binding data sourced from Markowitz 2013 paper - web retrieval only, cannot access full text directly |
| 11 | WebSearch | isopropylphenidate legal status scheduling UK US EU Australia 2024 | 10 | 4 | Legal status data for major jurisdictions |
| 12 | PubMed | methylphenidate MDMA co-administration interaction serotonin cardiovascular | 1 | 1 | Direct evidence for MPH-class+MDMA dangerous cardiovascular interaction |
| 13 | WebSearch | isopropylphenidate legal status UK US Germany Canada Australia | 20 | 3 | Legal status across major jurisdictions |
| 14 | Grokipedia (web_retrieved) | isopropylphenidate binding affinity specific values | 1 | 3 | Only available numerical binding data; flagged as requiring full-text verification |
| 15 | WebSearch | stimulant tramadol dangerous interaction seizure serotonin | 10 | 2 | Mechanism for tramadol 'lethal' interaction with IPH |
| 16 | Multiple sources | Verification of chemical data against PubChem and secondary sources | 3 | 3 | Chemical identity cross-verification |
| 17 | PubMed | methylphenidate adverse effects cardiovascular hypertension clinical review | 4 | 2 | Overdose management and cardiovascular data directly applicable to IPH as MPH analog |
61 claims by section — every cited sentence, checked against its source
pharmacology13 · 6 ok
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
This resistance has two major consequences: sustained pharmacological action beyond methylphenidate's typical 2–3 hour effective window, and substantially reduced ethanol interaction via the CES1-mediated transesterification pathway that converts methylphenidate to ethylphenidate in the presence of alcohol.supported
greater resistance to hydrolysis and transesterification via CES1 relative to MPH. Sustained psychostimulant properties in rats with locomotor activity as pharmacodynamic outcome. cap.2013.0074
This resistance has two major consequences: sustained pharmacological action beyond methylphenidate's typical 2–3 hour effective window, and substantially reduced ethanol interaction via the CES1-mediated transesterification pathway that converts methylphenidate to ethylphenidate in the presence of alcohol.supported
CES1-mediated enantioselective hydrolysis and transesterification. Relevant to IPH's reduced CES1 hydrolysis and reduced ethanol interaction risk. dmd.112.048595
Claim in pharmacology — inconclusiveinconclusiveworking →
Manier and colleagues identified 17 metabolites of IPH in rat urine using ultra-high-performance liquid chromatography–high-resolution tandem mass spectrometry (UHPLC-HRMS/MS): 14 phase I metabolites and 3 phase II metabolitessupported
Identified 17 metabolites of IPH (14 phase I, 3 phase II) in rat urine using UHPLC-HRMS/MS. bkz052
Claim in pharmacology — inconclusiveinconclusiveworking →
Carboxy metabolites are recommended as analytical targets alongside the parent compound for toxicological screening.supported
Carboxy metabolites recommended as additional analytical targets for comprehensive screening. bkz052
By analogy with ethylphenidate, the closest well-studied phenidate analog, CYP2C19 is likely the most active oxidative isoform, with contributions from CYP1A2, CYP2B6, CYP2C9, CYP2D6, and CYP3A4.supported
CYP2C19 most active. rCYP1A2, 2B6, 2C9, 2D6, 3A4 also involved. j.jpba.2015.09.029
Claim in pharmacology — inconclusiveinconclusiveworking →
The duration data available (oral total 3.5–6 hours, insufflated total 2.5–4 hours) derive exclusively from user self-reports and are consistent with the animal data demonstrating sustained activity relative to methylphenidate.supported
Sustained psychostimulant properties in rats with locomotor activity as pharmacodynamic outcome. cap.2013.0074
safety11 · 10 ok
The closely related ethylphenidate has been associated with 7 documented fatalities, establishing that phenidate-class analogs carry real toxicity risk despite the absence of IPH-specific fatality data.supported
7 cases with ethylphenidate (EPH) detected in postmortem blood (Feb 2013-Jan 2015). All male, ages 23-49. One case sole EPH toxicity; 4 mixed drug toxicity; 2 hangings. j.forsciint.2015.12.045
Given IPH's mechanism as a DAT/NET reuptake inhibitor, its acute overdose toxicology is expected to parallel methylphenidate overdose presentations. Anticipated features include:supported
MPH overdose features mydriasis, tremor, agitation, hyperreflexia, hallucinations, delirium, seizures. Mechanism: excessive DA/NE/5-HT. s40263-013-0084-8
{{Emergency}}In suspected isopropylphenidate overdose, management follows methylphenidate/stimulant overdose protocol: benzodiazepines as first-line treatment for agitation and seizures, supportive cardiovascular management, continuous temperature monitoring, and poison control consultation.{{/Emergency}}supported
Management: benzodiazepines first-line; antipsychotics for refractory cases. s40263-013-0084-8
Tolerance to stimulant effects is expected with repeated administration, following the methylphenidate pattern of locomotor tolerance without behavioral sensitizationsupported
Chronic MPH administration produces tolerance to locomotor activity (not sensitization like amphetamine). pmid:8332631
IPH's slower CES1 metabolism may confer somewhat reduced abuse liability compared to methylphenidate by reducing the rapid rise-and-fall plasma kinetics that drive reinforcement cyclessupported
greater resistance to hydrolysis and transesterification via CES1 relative to MPH. Sustained psychostimulant properties in rats. cap.2013.0074
Claim in safety — inconclusiveinconclusiveworking →
Tramadol inhibits serotonin and norepinephrine reuptake (SNRI-like action) and significantly lowers the seizure thresholdsupported
Tramadol inhibits serotonin and norepinephrine reuptake; seizures and serotonin syndrome are two significant adverse reactions. pmid:19724727
Tramadol inhibits serotonin and norepinephrine reuptake (SNRI-like action) and significantly lowers the seizure thresholdsupported
Tramadol's SNRI activity underlies serotonin syndrome and seizure risks. j.amjmed.2018.04.025
A human randomized controlled trial demonstrated that methylphenidate (0.5 mg/kg) combined with MDMA (125 mg) produced significantly elevated cardiovascular adverse effects (heart rate, blood pressure) compared to either drug alone, without enhancement of desired subjective effectssupported
MPH+MDMA in healthy subjects: combination does not increase psychoactive effects but significantly enhances cardiovascular and adverse effects compared to either alone. s1461145713001132
IPH's 10-fold CES1 resistance substantially reduces the transesterification pathway (methylphenidate + ethanol → ethylphenidate) that represents a pharmacokinetic drug interaction specific to methylphenidatesupported
greater resistance to hydrolysis and transesterification via CES1 relative to MPH. cap.2013.0074
IPH's 10-fold CES1 resistance substantially reduces the transesterification pathway (methylphenidate + ethanol → ethylphenidate) that represents a pharmacokinetic drug interaction specific to methylphenidatesupported
CES1-mediated enantioselective hydrolysis and transesterification. Relevant to IPH's reduced CES1 hydrolysis and reduced ethanol interaction risk. dmd.112.048595
comparative-pharmacology9 · 3 ok
EPH has been associated with 7 documented fatalities, while no fatalities have been attributed to IPHsupported
7 cases with ethylphenidate (EPH) detected in postmortem blood (Feb 2013-Jan 2015). j.forsciint.2015.12.045
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Ethylphenidate (EPH) shares IPH's enhanced DAT selectivity but differs in metabolic stability and safety profile. d-EPH shows near-exclusive DAT action with minimal NET involvementsupported
d-EPH selectively targets DAT; CES1 transesterification of MPH with ethanol. jps.24202
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Within the broader novel psychoactive stimulant landscape, IPH is notable for its relatively clean pharmacological profile (selective DAT inhibition without releasing activity, serotonergic effects, or off-target receptor binding), its sustained duration, and its reduced ethanol interaction liabilitysupported
Stimulants including phenidate analogs interact primarily with monoamine transporters, causing sympathomimetic adverse effects. s00204-020-02693-7
chemistry6 · 5 ok
This single substitution increases steric bulk and lipophilicity at the ester position, conferring resistance to enzymatic hydrolysis by carboxylesterase-1 (CES1).supported
greater resistance to hydrolysis and transesterification via CES1 relative to MPH. cap.2013.0074
Froimowitz and colleagues systematically explored alkyl ester modifications to the methylphenidate scaffold, establishing that increased ester chain length and branching generally enhances DAT selectivity and prolongs duration of action.supported
MPH analogues with alkyl ester substitutions tested in monoamine transporter assays. Some show slow onset and long duration with enhanced DAT selectivity. pmid:17228864
Commercial and research samples of IPH are prepared exclusively in the threo configurationsupported
Full characterization (X-ray, NMR, GC-MS, FTIR) of six phenidate analogs. Exclusive threo-configuration. dta.2161
The racemic threo mixture (dl-IPH) was used in the Markowitz 2013 characterizationsupported
Investigated metabolic profiles and pharmacological activity of dl-isopropylphenidate (IPH) in vitro and in vivo. cap.2013.0074
Claim in chemistry — inconclusiveinconclusiveworking →
Phenidate analogs as a class exhibit thermal instability under gas chromatography–mass spectrometry (GC-MS) conditions, with decomposition occurring in the injection port; liquid chromatography–tandem mass spectrometry (LC-MS/MS) is therefore the preferred analytical method for forensic identification.supported
Full characterization (X-ray, NMR, GC-MS, FTIR) of six phenidate analogs. Thermal decomposition in GC-MS. dta.2161
clinical-evidence5 · 3 ok
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Manier and colleagues conducted in vitro metabolite identification using rat urine and human S9 fractions, establishing the metabolic profile for forensic and clinical analytical purposessupported
Identified 17 metabolites of IPH (14 phase I, 3 phase II) in rat urine using UHPLC-HRMS/MS. Human S9 fraction indicated primary hydrolysis to carboxy metabolites. bkz052
In the absence of clinical evidence, isopropylphenidate has been adopted by individuals self-medicating for ADHD symptoms and cognitive enhancement, a pattern documented in qualitative research on novel psychoactive substance usesupported
Subjects mainly self-treating ADHD, anxiety, depression. 4F-MPH (a phenidate) among most discussed. Motivations include access, cost, legality, dissatisfaction with healthcare. j.drugpo.2023.104109
In the absence of clinical evidence, isopropylphenidate has been adopted by individuals self-medicating for ADHD symptoms and cognitive enhancement, a pattern documented in qualitative research on novel psychoactive substance usesupported
Growing availability of NPS as cognitive enhancers. Internet/psychonaut-reported use patterns. Identifies phenidate analogs among commonly reported cognitive enhancers. fpsyt.2020.546796
receptor-pharmacology5 · 3 ok
The primary pharmacological characterization of isopropylphenidate derives from Markowitz and colleagues, who assessed monoamine transporter inhibition using rat synaptosome and HEK293 transfected cell assays.supported
Investigated metabolic profiles and pharmacological activity of dl-isopropylphenidate (IPH) in vitro and in vivo. cap.2013.0074
Markowitz and colleagues concluded that IPH exhibits "greater DAT than NET binding and cellular uptake activity," qualitatively confirming selective dopaminergic action over noradrenergic. The specific IC₅₀ values (DAT ~200 nM, NET >10,000 nM) are aggregated from secondary sources citing Markowitz 2013; full-text verification of these exact numerical values is required.supported
IPH displayed greater DAT than NET binding and cellular uptake activity. cap.2013.0074
Luethi and colleagues characterized the pharmacological profile of IPH and related methylphenidate-based designer drugs in vitro using HEK293 cells transfected with human DAT, NET, and SERTsupported
In vitro pharmacological characterization of methylphenidate-based NPS including IPH. Characterizes DAT/NET/SERT binding and uptake inhibition. j.neuropharm.2017.08.020
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
history4 · 1 ok
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
The compound was adopted primarily by individuals seeking cognitive enhancement or self-medicating for ADHD symptoms.supported
Subjects mainly self-treating ADHD, anxiety, depression. 4F-MPH (a phenidate) among most discussed. Motivations include access, cost, legality, dissatisfaction with healthcare. j.drugpo.2023.104109
summary4 · 1 ok
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
As a DAT/NET reuptake inhibitor, cardiovascular toxicity (tachycardia, hypertension) represents the primary acute risk at supratherapeutic doses, following the methylphenidate overdose profilepartially supported
MPH overdose features mydriasis, tremor, agitation, hyperreflexia, hallucinations, delirium, seizures. Mechanism: excessive DA/NE/5-HT. s40263-013-0084-8
neuroscience2 · 2 ok
Chronic methylphenidate administration in rodents produces tolerance to locomotor effects rather than sensitization — a pattern that distinguishes phenidates from amphetamines, which characteristically produce behavioral sensitization with repeated dosingsupported
Chronic MPH administration produces tolerance to locomotor activity (not sensitization like amphetamine). Suggests different mechanisms of tolerance development between reuptake blockers and releasers. pmid:8332631
Is the tolerance profile (tolerance without sensitization) confirmed in primates or humans? The rat data from McNamara 1993 apply to methylphenidate; IPH-specific tolerance neuroadaptation is unstudied.supported
Chronic MPH administration produces tolerance to locomotor activity (not sensitization like amphetamine). Suggests different mechanisms of tolerance development between reuptake blockers and releasers. pmid:8332631
pharmacokinetic-detail2 · 2 ok
Structural analog inference from ethylphenidate suggests CYP2C19 as the primary oxidative isoform, with secondary contributions from CYP1A2, CYP2B6, CYP2C9, CYP2D6, and CYP3A4. Individuals who are CYP2C19 poor metabolizers may experience prolonged effects if this isoform is relevant to IPH oxidative metabolism, but this has not been studied.supported
CYP2C19 most active. rCYP1A2, 2B6, 2C9, 2D6, 3A4 also involved. j.jpba.2015.09.029
CYP-mediated drug interactions are likely less clinically significant given that oxidative metabolism appears to be a secondary pathwaysupported
Human S9 fraction indicated primary hydrolysis to carboxy metabolites. bkz052